Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Is a Microsatellite Instability Still Useful for Tailored Treatment in Stage II and III Colon Cancer?

Kim NK.

Ann Coloproctol. 2014 Feb;30(1):5-6. doi: 10.3393/ac.2014.30.1.5. No abstract available.

2.

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S.

N Engl J Med. 2003 Jul 17;349(3):247-57.

3.

Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis.

Guidoboni M, Gafà R, Viel A, Doglioni C, Russo A, Santini A, Del Tin L, Macrì E, Lanza G, Boiocchi M, Dolcetti R.

Am J Pathol. 2001 Jul;159(1):297-304.

4.

[Association between microsatellite instability and clinico-pathological characteristics in sporadic colon cancer].

Guerrero D, Balen E, Martínez-Peñuela JM, García-Foncillas J, Larrinaga B, Caballero MC, Herrera J, Lera JM.

Med Clin (Barc). 2005 Apr 2;124(12):441-6. Spanish.

PMID:
15826579
5.

Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.

Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S.

Ann Oncol. 2015 Jan;26(1):126-32. doi: 10.1093/annonc/mdu499. Epub 2014 Oct 30.

PMID:
25361982
6.

Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level.

Samowitz WS, Curtin K, Ma KN, Schaffer D, Coleman LW, Leppert M, Slattery ML.

Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):917-23.

7.

Prognostic and predictive significance of MSI in stages II/III colon cancer.

Saridaki Z, Souglakos J, Georgoulias V.

World J Gastroenterol. 2014 Jun 14;20(22):6809-14. doi: 10.3748/wjg.v20.i22.6809. Review.

8.

Microsatellite instability status does not predict total lymph node or negative lymph node retrieval in stage III colon cancer.

MacQuarrie E, Arnason T, Gruchy J, Yan S, Drucker A, Huang WY.

Hum Pathol. 2012 Aug;43(8):1258-64. doi: 10.1016/j.humpath.2011.10.002. Epub 2012 Feb 2.

PMID:
22305240
9.

1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer.

Mayrhofer M, Kultima HG, Birgisson H, Sundström M, Mathot L, Edlund K, Viklund B, Sjöblom T, Botling J, Micke P, Påhlman L, Glimelius B, Isaksson A.

BMC Cancer. 2014 Nov 24;14:872. doi: 10.1186/1471-2407-14-872.

10.

Microsatellite instability did not predict individual survival in sporadic stage II and III rectal cancer patients.

Meng WJ, Sun XF, Tian C, Wang L, Yu YY, Zhou B, Gu J, Xia QJ, Li Y, Wang R, Zheng XL, Zhou ZG.

Oncology. 2007;72(1-2):82-8. Epub 2007 Nov 14.

PMID:
18004081
11.

Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB 3rd, Hamilton SR.

N Engl J Med. 2001 Apr 19;344(16):1196-206.

12.

Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence.

Belt EJ, Stockmann HB, Delis-van Diemen PM, Bril H, Tijssen M, van Essen HF, Heymans MW, Beliën JA, Carvalho B, Cillessen SA, Meijer GA.

J Surg Oncol. 2014 Mar;109(3):255-65. doi: 10.1002/jso.23495. Epub 2013 Nov 19.

PMID:
24249458
13.

Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.

de Cuba EM, Snaebjornsson P, Heideman DA, van Grieken NC, Bosch LJ, Fijneman RJ, Belt E, Bril H, Stockmann HB, Hooijberg E, Punt CJ, Koopman M, Nagtegaal ID, Coupé VH, Carvalho B, Meijer GA.

Int J Cancer. 2016 Mar 1;138(5):1139-45. doi: 10.1002/ijc.29855. Epub 2015 Oct 23.

14.

Prognostic factors in sporadic colon cancer with high-level microsatellite instability.

Oh BY, Huh JW, Park YA, Cho YB, Yun SH, Kim HC, Lee WY, Chun HK.

Surgery. 2016 May;159(5):1372-81. doi: 10.1016/j.surg.2015.11.028. Epub 2016 Jan 8.

PMID:
26775578
15.

Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.

Belt EJ, Fijneman RJ, van den Berg EG, Bril H, Delis-van Diemen PM, Tijssen M, van Essen HF, de Lange-de Klerk ES, Beliën JA, Stockmann HB, Meijer S, Meijer GA.

Eur J Cancer. 2011 Aug;47(12):1837-45. doi: 10.1016/j.ejca.2011.04.025. Epub 2011 May 27.

16.

Colon and rectal cancer survival by tumor location and microsatellite instability: the Colon Cancer Family Registry.

Phipps AI, Lindor NM, Jenkins MA, Baron JA, Win AK, Gallinger S, Gryfe R, Newcomb PA.

Dis Colon Rectum. 2013 Aug;56(8):937-44. doi: 10.1097/DCR.0b013e31828f9a57.

17.

Microsatellite instability and p53 mutations in sporadic right and left colon carcinoma: different clinical and molecular implications.

Lleonart ME, García-Foncillas J, Sánchez-Prieto R, Martín P, Moreno A, Salas C, Ramón y Cajal S.

Cancer. 1998 Sep 1;83(5):889-95.

PMID:
9731891
18.

Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.

Dienstmann R, Salazar R, Tabernero J.

J Clin Oncol. 2015 Jun 1;33(16):1787-96. doi: 10.1200/JCO.2014.60.0213. Epub 2015 Apr 27. Review.

PMID:
25918287
19.

Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer.

Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K, Boland CR.

Gastroenterology. 2004 Feb;126(2):394-401.

PMID:
14762775
20.

Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer.

Ishiguro M, Mochizuki H, Tomita N, Shimada Y, Takahashi K, Kotake K, Watanabe M, Kanemitsu Y, Ueno H, Ishikawa T, Uetake H, Matsui S, Teramukai S, Sugihara K.

BMC Cancer. 2012 Jul 7;12:281.

Supplemental Content

Support Center